Agilent, Merck deal

Agilent's Dako company and Merck partnered to develop a companion diagnostic to assess levels of programmed cell death 1 ligand 1 ( PD-L1; B7-H1; CD274) in tumors. The developed test will be evaluated as part of Merck's clinical development program for pembrolizumab, a humanized IgG4 mAb against PD-1 receptor ( PDCD1; PD-1; CD279). The companies said financial details are not disclosed. ...